REAL-WORLD IMPACT OF TRIPLE THERAPY WITH FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL ON ASTHMA CONTROL AMONG US PATIENTS WITH ASTHMA

被引：0
|
作者：
Bogart, Michael
Germain, Guillaume
Laliberte, Frakois
Mahendran, Malena
Duh, Mei S.
机构：
来源：
CHEST | 2022年 / 162卷 / 04期
关键词：
D O I：
10.1016/j.chest.2022.08.1598
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1930A / 1931A
页数：2
相关论文
共 50 条
  • [1] Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
    Bogart, Michael
    Germain, Guillaume
    Laliberte, Francois
    Mahendran, Malena
    Duh, Mei Sheng
    Dirocco, Kristi
    Noorduyn, Stephen G.
    Paczkowski, Rosirene
    Balkissoon, Ronald
    JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 1309 - 1322
  • [2] REAL-WORLD ADHERENCE TO SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL VERSUS MULTIPLE-INHALER TRIPLE THERAPY AMONG ASTHMA PATIENTS IN THE US
    Averell, C.
    Germain, G.
    Laliberte, F.
    MacKnight, S.
    Jung, Y.
    Duh, M. S.
    Abbott, C.
    VALUE IN HEALTH, 2021, 24 : S13 - S13
  • [3] Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan
    Oga, Toru
    Mita, Chifuku
    Ito, Risako
    Requena, Gema
    Rothnie, Kieran J.
    Noorduyn, Stephen G.
    Yuanita, Liza
    Yarita, Masao
    RESPIRATORY INVESTIGATION, 2024, 62 (04) : 685 - 694
  • [4] Characterization of Patients with Asthma Initiating Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Wrobleski, Kristin
    Noorduyn, Stephen
    Lee, Lydia
    Igboekwe, Emmeline
    Liu, Meixia
    Veeranki, Phani
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB101 - AB101
  • [5] The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety
    Lipson, D. A.
    Criner, G.
    Dransfield, M. T.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Pascoe, S.
    Singh, D.
    Wise, R. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [6] The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status
    Halpin, D. M. G.
    Bardsley, S.
    Criner, G.
    Dransfield, M.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    Lange, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [7] Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
    Day, Nicola C.
    Kumar, Subramanya
    Criner, Gerard
    Dransfield, Mark
    Halpin, David M. G.
    Han, MeiLan K.
    Jones, C. Elaine
    Kaisermann, Morrys C.
    Kilbride, Sally
    Lange, Peter
    Lomas, David A.
    Martin, Neil
    Martinez, Fernando J.
    Singh, Dave
    Wise, Robert
    Lipson, David A.
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [8] Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
    Nicola C. Day
    Subramanya Kumar
    Gerard Criner
    Mark Dransfield
    David M. G. Halpin
    MeiLan K. Han
    C. Elaine Jones
    Morrys C. Kaisermann
    Sally Kilbride
    Peter Lange
    David A. Lomas
    Neil Martin
    Fernando J. Martinez
    Dave Singh
    Robert Wise
    David A. Lipson
    Respiratory Research, 21
  • [9] REDUCTION OF ASTHMA EXACERBATIONS FOLLOWING INITIATION OF SINGLE-INHALER TRIPLE THERAPY WITH FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN US CLINICAL CARE
    Bogart, Michael
    Germain, Guillaume
    Laliberte, Francois
    Mahendran, Malena
    Duh, Mei S.
    Dirocco, Kristi
    Noorduyn, Stephen G.
    Paczkowski, Rosirene
    Balkissoon, Ronald C.
    CHEST, 2023, 164 (04) : 6527A - 6528A
  • [10] The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age
    Criner, G. J.
    Dransfield, M.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345